
Second- and Third-Generation TKI Combo Therapies Are at the Forefront of Frontline Ph+ ALL Investigations
Ponatinib (Iclusig) plus blinatumomab (Blincyto) and dasatinib (Sprycel) plus inotuzumab ozogamicin (Besponsa) represent notable combination therapy approaches with TKIs under evaluation in the frontline Philadelphia chromosome–positive (Ph-positive) acute …